ECOR•electroCore reported results from a four-week randomized study of 541 participants, with 250 meeting final analysis criteria. Several treatment approaches showed symptom improvements versus monitoring alone, but none demonstrated statistically significant superiority.
The study found symptom improvements with cervical vagus nerve stimulation, Sonocea’s acoustic technology and their combination compared with monitoring alone. No active treatment demonstrated statistically significant superiority. The open-label study had no sham control and relied primarily on patient-reported outcomes, so the findings remain hypothesis-generating. Neither technology has FDA clearance or approval for Long COVID, and its safety and effectiveness for the condition remain unestablished.
